lemborexant
Adjunctive therapy • Brands: DAYVIGO
Last reviewed: 2025-12-28
General information
- Class: Adjunctive therapy
- Common US brands: DAYVIGO
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-28
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Dual orexin receptor antagonist (DORA); orexin OX1R/OX2R antagonist.
Metabolism & Half‑life
- Metabolism: CYP3A4
- Half‑life: Single-dose mean 18 h; Single-dose range 17–19 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Dayvigo (lemborexant) prescribing information — DailyMed (2025)
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)
- Efficacy and Acceptability of Pharmacological Interventions for Insomnia in Patients With Severe Mental Illness — Acta Psychiatrica Scandinavica (2025)
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)